PL2308838T3 - Aromatyczne związki heterocyklilowe zawierające azot - Google Patents

Aromatyczne związki heterocyklilowe zawierające azot

Info

Publication number
PL2308838T3
PL2308838T3 PL09794416T PL09794416T PL2308838T3 PL 2308838 T3 PL2308838 T3 PL 2308838T3 PL 09794416 T PL09794416 T PL 09794416T PL 09794416 T PL09794416 T PL 09794416T PL 2308838 T3 PL2308838 T3 PL 2308838T3
Authority
PL
Poland
Prior art keywords
nitrogen
containing aromatic
aromatic heterocyclyl
heterocyclyl compound
compound
Prior art date
Application number
PL09794416T
Other languages
English (en)
Inventor
Keiko Suzuki
Takahiro Yamaguchi
Akihiro Tamura
Tomohiro Nishizawa
Mitsuhiro Yamaguchi
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of PL2308838T3 publication Critical patent/PL2308838T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
PL09794416T 2008-07-08 2009-07-07 Aromatyczne związki heterocyklilowe zawierające azot PL2308838T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008178377 2008-07-08
EP09794416.9A EP2308838B1 (en) 2008-07-08 2009-07-07 Nitrogen-containing aromatic heterocyclyl compound
PCT/JP2009/062331 WO2010004972A1 (ja) 2008-07-08 2009-07-07 含窒素芳香族ヘテロシクリル化合物

Publications (1)

Publication Number Publication Date
PL2308838T3 true PL2308838T3 (pl) 2016-08-31

Family

ID=41507085

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09794416T PL2308838T3 (pl) 2008-07-08 2009-07-07 Aromatyczne związki heterocyklilowe zawierające azot

Country Status (24)

Country Link
US (2) US8648103B2 (pl)
EP (1) EP2308838B1 (pl)
JP (1) JP5461398B2 (pl)
KR (1) KR20110025742A (pl)
CN (1) CN102149680B (pl)
AU (1) AU2009269178B2 (pl)
BR (1) BRPI0915473A2 (pl)
CA (1) CA2730078A1 (pl)
CO (1) CO6341610A2 (pl)
CY (1) CY1117503T1 (pl)
DK (1) DK2308838T3 (pl)
ES (1) ES2566529T3 (pl)
HR (1) HRP20160236T1 (pl)
HU (1) HUE028595T2 (pl)
IL (1) IL210498A0 (pl)
MX (1) MX2011000044A (pl)
NZ (1) NZ590790A (pl)
PL (1) PL2308838T3 (pl)
RU (1) RU2481330C2 (pl)
SI (1) SI2308838T1 (pl)
SM (1) SMT201600119B (pl)
TW (1) TWI435875B (pl)
WO (1) WO2010004972A1 (pl)
ZA (1) ZA201100183B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2566529T3 (es) * 2008-07-08 2016-04-13 Daiichi Sankyo Company, Limited Compuesto heterociclilo aromático que contiene nitrógeno
WO2012147916A1 (ja) 2011-04-28 2012-11-01 日本たばこ産業株式会社 アミド化合物およびその医薬用途
US20160137639A1 (en) * 2012-10-26 2016-05-19 Japan Tobacco Inc. Triazole-isoxazole compound and medical use thereof
WO2014073989A1 (en) * 2012-11-12 2014-05-15 Callaghan Innovation Research Limited Salt and polymorphic forms of (3r,4s)-l-((4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4(methylthiomethyl)pyrodin-3-ol(mtdia)
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
ME03794B (me) 2016-05-31 2021-04-20 Kalvista Pharmaceuticals Ltd Derivati pirazola kao inhibitori kalikreina plazme
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
PL3716952T3 (pl) 2017-11-29 2022-05-02 Kalvista Pharmaceuticals Limited Postacie dawkowania zawierające inhibitor kalikreiny osoczowej
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
KR20260041885A (ko) 2023-07-25 2026-03-27 몬테 로사 테라퓨틱스 아게 표적화된 단백질 분해를 위한 치환된 피페리딘디온

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ548212A (en) 2003-12-29 2010-07-30 Sepracor Inc Pyrrole and pyrazole DAAO inhibitors
JP2008518957A (ja) 2004-11-04 2008-06-05 メルク エンド カムパニー インコーポレーテッド ナイアシン受容体作動薬、そのような化合物を含んでいる組成物及び治療方法
EP1811996A1 (en) 2004-11-05 2007-08-01 Arena Pharmaceuticals, Inc. Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists
JP2008520715A (ja) 2004-11-23 2008-06-19 メルク エンド カムパニー インコーポレーテッド ナイアシン受容体アゴニスト、そのような化合物を含む組成物、および治療方法
GB0503053D0 (en) 2005-02-14 2005-03-23 Smithkline Beecham Corp Chemical compounds
GB0505735D0 (en) 2005-03-21 2005-04-27 Glaxo Group Ltd Compounds
CA2611552A1 (en) 2005-06-28 2007-01-04 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
WO2007015744A1 (en) * 2005-07-21 2007-02-08 Incyte Corporation Disubstituted thienyl compounds and their use as pharmaceuticals
DE602006012358D1 (de) * 2005-11-18 2010-04-01 Dabur Pharma Ltd Zielgerichtete fusionsproteine für die krebstherapie
EP1792901A1 (en) * 2005-11-22 2007-06-06 Bayer CropScience S.A. N-(1-alkyl-2-phenylethyl)-carboxamide derivatives and use thereof as fungicides
CA2633042A1 (en) 2005-12-20 2007-07-05 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
CA2641307A1 (en) 2006-02-07 2007-08-16 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
EP2010512A4 (en) 2006-04-11 2010-02-24 Merck & Co Inc Niacin receptor agonists, compositions containing such compounds and method of treatment
ES2566529T3 (es) * 2008-07-08 2016-04-13 Daiichi Sankyo Company, Limited Compuesto heterociclilo aromático que contiene nitrógeno

Also Published As

Publication number Publication date
EP2308838B1 (en) 2016-02-17
US8648103B2 (en) 2014-02-11
HRP20160236T1 (hr) 2016-05-06
IL210498A0 (en) 2011-03-31
CN102149680A (zh) 2011-08-10
EP2308838A1 (en) 2011-04-13
TWI435875B (zh) 2014-05-01
US20120108639A1 (en) 2012-05-03
RU2481330C2 (ru) 2013-05-10
US9150563B2 (en) 2015-10-06
TW201004950A (en) 2010-02-01
DK2308838T3 (da) 2016-05-17
WO2010004972A1 (ja) 2010-01-14
KR20110025742A (ko) 2011-03-11
BRPI0915473A2 (pt) 2015-11-10
RU2011104223A (ru) 2012-08-20
CY1117503T1 (el) 2017-04-26
JP5461398B2 (ja) 2014-04-02
CN102149680B (zh) 2014-12-10
ES2566529T3 (es) 2016-04-13
NZ590790A (en) 2012-09-28
MX2011000044A (es) 2011-02-22
EP2308838A4 (en) 2012-05-09
HUE028595T2 (en) 2016-12-28
ZA201100183B (en) 2012-06-27
US20140187592A1 (en) 2014-07-03
SI2308838T1 (sl) 2016-09-30
CA2730078A1 (en) 2010-01-14
AU2009269178B2 (en) 2012-09-06
HK1155443A1 (en) 2012-05-18
JPWO2010004972A1 (ja) 2012-01-05
SMT201600119B (it) 2016-07-01
AU2009269178A1 (en) 2010-01-14
CO6341610A2 (es) 2011-11-21

Similar Documents

Publication Publication Date Title
ZA201100183B (en) Nitrogen-containing aromatic heterocyclyl compound
TWI367207B (en) Substituted pyrrolidine-2-carboxamides
GB0812648D0 (en) Compounds
GB0812649D0 (en) Compounds
IL231955A0 (en) Tetracycline compounds are substituted at the 7c position with fluorine
GB0804989D0 (en) Compound
GB0819287D0 (en) Compounds
GB0821616D0 (en) Compounds
IL208281A0 (en) Substituted cyclohexyldiamines
IL209175A0 (en) Substituted qunazolines
GB0803494D0 (en) Compound
IL207035A0 (en) Benzylpiperizine compound
GB0823316D0 (en) Compound
GB0801220D0 (en) Compounds
SI2340021T1 (sl) Substituirani pirolidin-2-karboksamidi
GB0809103D0 (en) Aromatic affected
IL210015A0 (en) Substituted cyclohexylidene-ethylidene-octahydro-indene compounds
GB0806844D0 (en) Compound
GB0822635D0 (en) Compound
GB0802193D0 (en) Compound
GB0820916D0 (en) Compound
GB0807160D0 (en) Compound
GB0806005D0 (en) Compound
GB0807158D0 (en) Compound
GB0820915D0 (en) Compound